Quick Facts

• Primary Use: Management of chronic excess body weight in adults.
• Eligibility: Indicated for adults with a Body Mass Index (BMI) of 30 kg/m^2 or greater, or a BMI of 27 kg/m^2 or greater when one or more weight-related conditions (such as high blood pressure or type 2 diabetes) are present.
• Therapeutic Context: Used as an adjunct to a reduced-calorie diet and increased physical activity.

---

What Obesan-X treats: main uses and benefits

Obesan-X is a prescription medication utilized for the chronic weight management of adults who are living with excess weight. It is indicated for patients with an initial Body Mass Index (BMI) of 30 kg/m^2 or greater (categorized as obesity), or for those with a BMI of 27 kg/m^2 or greater who also have at least one weight-related comorbidity, such as high blood pressure or type 2 diabetes. The therapeutic goal is to assist in weight reduction and maintenance of that weight reduction over time.

This medication is not a standalone treatment; it is intended to be used in conjunction with a reduced-calorie dietary regimen and an appropriate program of physical activity. It may help to influence factors related to appetite regulation and food intake, which can support the establishment of an appropriate energy balance. Clinical programs utilize Obesan-X to support patient efforts to achieve and sustain clinically relevant weight loss outcomes, thus potentially contributing to improved long-term health outlooks.

Who Can and Cannot Use Obesan-X?

Obesan-X (Phendimetrazine) is a prescription medication with strictly defined eligibility rules based on regulatory requirements. Use is indicated only for adults who meet specific Body Mass Index (BMI) criteria for exogenous obesity, serving as a short-term, adjunct treatment.

---

Absolute Contraindications (Must Not Use)

The medication is contraindicated and must not be used by patients with specific pre-existing conditions, including:

• Cardiovascular Disease: Individuals with a history of heart conditions, including advanced arteriosclerosis, symptomatic cardiovascular disease, or uncontrolled hypertension.
• Metabolic/Ocular: Those with hyperthyroidism or glaucoma.
• Psychological/Substance Use: Patients in an agitated state or those with a history of drug abuse.
• Concomitant Use: Individuals taking Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of use, or other anorectic agents.

---

Population Restrictions

Population Group	Eligibility Status
Pediatric Patients (<17)	Not Recommended; safety and effectiveness are not established.
Pregnant or Nursing Women	Contraindicated; weight loss is not advised during these periods.
Elderly Patients	Caution is advised; dose selection should be cautious due to organ function changes.

Conditional Use: Caution is also required for patients with conditions such as diabetes mellitus or renal impairment, as these may alter the required management approach.

Interactions with other medicines and products

Official regulatory documents classify several substance categories and specific medicinal products that interact with Obesan-X (Phendimetrazine Tartrate). These documented interactions establish mandatory constraints on co-administration, primarily concerning the risk of severe adverse pharmacodynamic effects or alterations in drug exposure.

---

Contraindicated Combinations

Classification	Interacting Agents
Pharmacodynamic Synergism	Monoamine Oxidase Inhibitors (MAOIs): Use is contraindicated during or within 14 days following MAOI administration due to the risk of hypertensive crisis.
Cardiovascular Risk	Other Anorectic Agents / CNS Stimulants: Contraindicated for co-administration, including prescribed and herbal products, due to the potential for serious cardiac problems, such as pulmonary hypertension.

---

Pharmacodynamic and Exposure Interactions

Classification	Interacting Agents
Antagonism of Effect	Adrenergic Neuron Blocking Drugs: Phendimetrazine may decrease the hypotensive effect of these medicines.
Altered Drug Clearance	Acetazolamide: This medicine may decrease the excretion rate of Phendimetrazine, which could lead to increased systemic exposure.

---

Population and Substance-Specific Considerations

Regulatory information notes that for patients with Diabetes Mellitus, the requirements for Insulin and Oral Hypoglycemic Medications may be altered. Furthermore, co-administration with alcohol may result in an adverse drug reaction, and increased exposure is expected in patients with renal impairment.

Modulation of Receptor-Mediated Signaling

Obesan-X acts within domains involving receptor- or enzyme-mediated signaling by initiating or suppressing specific signaling sequences that lead to downstream effects. This core mechanism influences systems where specific transmitters or mediators dominate, resulting in the attenuation of activity within the targeted physiological system.

---

Targeted Pathway Adjustment

The drug modulates key pathways associated with heightened physiological responses by modifying early molecular steps that shape systemic physiological outcomes. This action is relevant in systems where targeted pathway adjustment is required, facilitating the shift toward a low-activity set-point within targeted pathways.

---

Regulation of Dysregulated Processes

Obesan-X engages mechanisms that regulate overactive or dysregulated processes and is applied in contexts involving rapid modulation of physiological responses. It is relevant in cascades where multiple layers of pathway activation occur, thereby decreasing the downstream signaling magnitude initiated by mediator activity and culminating in specific alterations to the physiological response profile.

How to Use Obesan-X

Obesan-X (phendimetrazine tartrate) is administered as an oral medication for short-term adjunctive use in weight management. Administration instructions are dictated by the specific formulation, which includes both immediate-release (IR) tablets and extended-release (ER) capsules.

---

Dosing and Schedule

The standard adult dosing regimens depend on the dosage form:

• Immediate-Release (IR) Tablet: The usual dose is 35 mg taken two or three times daily. This formulation must be administered 1 hour before meals. The maximum recommended intake is 70 mg (two tablets) up to three times per day.
• Extended-Release (ER) Capsule: The standard dose is 105 mg, administered once daily. This dose must be taken 30 to 60 minutes before the morning meal.

Administration Constraints

Treatment duration is limited; the medicine is indicated for use as a short-term adjunct for only a few weeks. The therapy must be discontinued if tolerance to the anorectic effect develops or if satisfactory weight loss is not achieved within the first four weeks of use.

To maintain the intended release profile, the ER capsule must be swallowed whole and should not be crushed, broken, or chewed. Administration should avoid late evening hours to mitigate the potential for insomnia. The medication is also strictly indicated for monotherapy and should not be used in combination with other anorectic agents.

For older adults, labeling recommendations suggest cautious dose selection, typically starting at the lower end of the dosing range.

Research evidence / Overview of Studies for Obesan-X

Evidence for Use in Exogenous Obesity

The medication was evaluated in research exploring its use as an adjunct to a physician-supervised weight reduction regimen that includes reduced caloric intake and physical activity. The core evidence for this use is derived from short-term Randomized Controlled Trials (RCTs). These studies included adult populations. Research examined outcomes in individuals categorized as having obesity (with an initial Body Mass Index, or BMI, of 30 kg/m^2 or higher) or in those who were overweight (BMI of 27 kg/m^2 or higher) and also presented with a weight-related comorbidity. The evidence contributes to understanding outcomes measured in trials involving changes in body mass and related physiological states.

How Studies Measured Weight Change

In the research conducted, studies explored specific outcomes related to the participants' body weight. The main outcomes monitored were the overall change in total body weight during the trial period and the rate at which that change occurred. These short-term trials often compared the outcomes of participants who received the drug alongside diet and exercise against groups who received an inactive placebo while following the same diet and exercise plan. Findings describe patterns observed in these studies where total body weight change was the primary measurement. Research highlights changes measured during the study period, and studies report how weight patterns evolved in the observed populations during the trials.

Long-Term Studies and Follow-Up Data

Research exploring short-term changes, like those for Obesan-X, typically restrict their follow-up durations to a few weeks. Because of this design, the core evidence base provides limited insight into long-term outcomes. Long-term effects are not fully established regarding the use of the drug over many months or years. While some retrospective and observational studies have tracked patient records for longer periods, the certainty remains low regarding sustained outcomes. Research exploring temporary physiological states indicates that the study results reflect the specific conditions and short timeframes under which they were conducted.

Evidence in Specific Patient Groups

Evidence in specific patient groups is limited. The main short-term studies focused exclusively on specific adult populations meeting the defined BMI and comorbidity criteria; therefore, results apply only to the populations studied. Research has not fully characterized the medication's use in other age groups. For example, data for certain groups, such as pediatric patients (children and adolescents), remain insufficient, and safety and effectiveness in this population have not been established. Similarly, there is limited information for older adults, who may be more likely to experience physiological differences that could alter observation patterns.

What Research Gaps and Uncertainty Remain

There are several areas where research is ongoing or where the evidence quality varies across studies. Evidence is limited concerning the ultimate impact of short-term use on crucial long-term health endpoints, such as cardiovascular disease incidence or mortality rates. Furthermore, existing studies describe patterns related to the development of tolerance to the effects being measured, which was observed in some studies within a few weeks, and research does not determine whether an individual will respond similarly. Finally, evidence highlights what is known (short-term patterns) and what is still uncertain (long-term health outcomes and sustained changes).

Key Studies & References

1. PHENDIMETRAZINE TARTRATE capsule, extended release - Official Prescribing Information (DailyMed)

Common questions about Obesan-X (FAQ)

---

Q: Is Obesan-X a type of GLP-1 drug, or does it work in a different way?

Official information describes Obesan-X as a Sympathomimetic Amine, which means it works by stimulating the central nervous system. This classification places it in a different drug category than medications like GLP-1 agonists. The drug's primary function is to help reduce appetite by influencing the appetite control center in the brain.

Q: Is Obesan-X approved for use in people who do not have type 2 diabetes?

Yes, Obesan-X is indicated for use as an adjunct therapy for exogenous obesity, based primarily on Body Mass Index (BMI) criteria, not the presence of Type 2 diabetes. Regulatory documents state that for patients who also have diabetes, careful monitoring of blood sugar levels may be necessary.

Q: What does the drug's official information say about its effectiveness?

Official clinical trials indicate that when Obesan-X is used alongside diet and exercise, patients lose more weight on average compared to those using only a placebo and diet. The official information describes the increase in weight loss compared to placebo as typically being a fraction of a pound a week. The drug is formally indicated for short-term support.

Q: What are the most common side effects reported with Obesan-X?

Official drug labeling does not assign frequency classifications (like 'common' or 'uncommon') to most adverse reactions. Documented side effects include reactions in the Central Nervous System such as insomnia, dizziness, and tremor, and Cardiovascular effects like palpitations and elevated blood pressure.

Q: Can people with a history of eating disorders or mental health conditions use this medicine?

Regulatory labeling explicitly states that the medicine is contraindicated for use in patients with a history of drug abuse. It is also forbidden for individuals who are in a highly nervous or agitated state. The official documentation does not use the specific phrase 'eating disorders,' but eligibility is constrained by psychological state.

Q: Is there an official list of medicines, including over-the-counter drugs, that interact with Obesan-X?

Yes, regulatory documents list specific substances that are absolutely contraindicated for co-administration. These include Monoamine Oxidase Inhibitors (MAOIs), other appetite-reducing agents, certain CNS stimulants, and some over-the-counter preparations and herbal products. These combinations are generally forbidden by regulatory authorities.

Q: Has the drug received any recent safety alerts or boxed warnings from regulatory agencies?

Official labeling highlights two key safety constraints. The drug is classified as a Schedule III controlled substance due to its potential for abuse. A major warning also notes that use for a duration longer than three months is associated with a significantly increased risk of developing Primary Pulmonary Hypertension (PPH).

Q: What happens if a person discontinues or stops using Obesan-X?

Official regulatory information cautions that abrupt cessation of the drug, particularly after prolonged use at high doses, can result in withdrawal symptoms. These symptoms may include signs of psychological dependence, such as extreme fatigue and mental depression.

Q: How long does it typically take for the effects of Obesan-X to start becoming noticeable?

The drug is specifically indicated only for short-term use. Regulatory evidence indicates that the appetite-reducing (anorectic) effect often begins to decline, or tolerance may develop, within the first few weeks of starting the therapy.

Q: Is nausea always an expected side effect when first starting Obesan-X?

Nausea is a documented adverse reaction within the gastrointestinal system listed in the regulatory information. However, official labeling does not classify the frequency or state that this side effect is always expected when starting the medicine.

Q: Is it necessary to separate the timing of Obesan-X from other oral medications?

While specific separation from every other medication is not listed, the administration of Obesan-X is tied to meal timing. The immediate-release tablet must be taken 1 hour before meals, and the extended-release capsule must be taken 30 to 60 minutes before the morning meal. Regulatory guidance emphasizes adherence to meal timing requirements.

Q: Is there an official Patient Information or Prescribing Information sheet available for Obesan-X?

Yes. The most detailed official information about the drug is contained in the FDA-approved Prescribing Information (also referenced as the FDA Label or DailyMed entry). This official document is provided to prescribers and is publicly accessible through regulatory databases.

Storage and Disposal Requirements

Obesan-X (Phendimetrazine Tartrate) storage and disposal must strictly adhere to regulatory requirements to ensure product integrity and safety.

---

Storage Conditions

Requirement	Specification
Temperature	Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection	Keep protected from light, moisture, and freezing.
Container	Must be stored in a tight and light-resistant container.
Safety	Store the product out of the reach and sight of children.

---

Disposal Instructions

Disposal must follow the Controlled Substance Protocol. Unused medicine should be discarded through an official drug take-back program. If this is not feasible, unused product must be mixed with an undesirable substance and placed in a sealed container before discarding in household trash. Disposal must prevent the medicine from entering sewers or waterways.